SCHEMBL204730

SCHEMBL204730

CCOC(=O)CC(OCC)OCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
ALDH1A1 P00352 7/20 0.46
TRPA1 O75762 1/20 0.46
ALOX15 P16050 3/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
HSD17B10 Q99714 2/20 0.41
CHRM1 P11229 1/20 0.41
ADORA1 P30542 1/20 0.41
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
SOAT1 P35610 1/20 0.39
CYP2D6 P10635 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4966366 0.89 MGAM (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL8574175 0.86 MGAM (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1881682 0.86 NAAA (0.38) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28071761 0.84 KDM4E (0.41) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL21081924 0.83 ALDH1A1 (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1879376 0.83 TSHR (0.39) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL10084506 0.83 SOAT1 (0.54) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL16415508 0.83 GAA (0.54) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1884754 0.81 NAAA (0.47) ALDH1A1TSHRTDP1L3MBTL1
SCHEMBL1879615 0.81 ALDH1A1 (0.42) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 754 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111296-A1 ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES USING THE SAME II-VI DELAWARE, INC. (US) 2025-05-30 WO claimed
US-20240376106-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR INCYTE CORPORATION 2024-11-14 US claimed
US-11780836-B2 Process of preparing a PD-1/PD-L1 inhibitor INCYTE CORPORATION (US) 2023-10-10 US claimed
CN-113640431-B Detection method of strong loquat dew 江西大自然制药有限公司 2023-05-12 CN claimed
WO-2022099018-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR INCYTE CORPORATION (US) 2022-05-12 WO claimed
US-20220144830-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR INCYTE CORPORATION 2022-05-12 US claimed
CN-114436809-A Method for preparing diethyl maleate by carrying out depolymerization on lignin under catalysis of iron oxide loaded by USY molecular sieve 华南理工大学 2022-05-06 CN claimed
CN-113640431-A Detection method of strong loquat syrup 江西大自然制药有限公司 2021-11-12 CN claimed
CN-108484497-B Synthetic method of 3-amino-7-chloroquinoline 苏州康润医药有限公司 2021-05-04 CN claimed
CN-111825670-A Tetrahydrocarboline derivative, preparation method thereof and application thereof in preparing antihypertensive drug 复旦大学 2020-10-27 CN claimed
CN-104230880-B The simple and convenient process for preparing of 2-((4R, 6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxane-4-yl) acetic acid esters XINFA PHARMACEUTICAL CO., LTD. (CN) 2016-05-04 CN claimed
CN-104230880-A Simple preparation method of 2-((4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxyhexacyclo-4-yl)acetate XINFA PHARMACEUTICAL CO LTD 2014-12-24 CN claimed
CN-104230990-A 2-((4R,6S)-6-triphenylphosphoalkenylmethylene-2,2-disubstituted-1,3-dioxyhexacyclo-4-yl)acetate, and preparation method and application thereof XINFA PHARMACEUTICAL CO LTD 2014-12-24 CN claimed
US-7034154-B2 Synthesis of substituted pyrazolopyrimidines NEUROCRINE BIOSCIENCES, INC. (US) 2006-04-25 US claimed
JP-2003506453-A 2003-02-18 JP claimed
US-20030004346-A1 Synthesis of substituted pyrazolopyrimidines NEUROCRINE BIOSCIENCES, INC. (US) 2003-01-02 US claimed
US-6472528-B1 TREATING CONDITIONS WHICH BENEFIT FROM ADMINISTRATION OF AGENTS WHICH POSSESS ANXIOLYTIC, ANTI-ANOXIC, SLEEP-INDUCING, HYPNOTIC, ANTICONVULSANT, AND/OR SKELETAL MUSCLE RELAXANT PROPERTIES. SUCH CONDITIONS INCLUDE INSOMNIA NEUROCRINE BIOSCIENCES, INC. 2002-10-29 US claimed
CN-1372561-A Synthesis of Substituted Pyrazolopyrimidines NEUROCRINE BIOSCIENCES INC (US) 2002-10-02 CN claimed
EP-1208102-A1 SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES Neurocrine Biosciences, Inc. (US) 2002-05-29 EP claimed
WO-2001010868-A1 SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES NEUROCRINE BIOSCIENCES, INC. (US) 2001-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004346-A1 Synthesis of substituted pyrazolopyrimidines INMT, TPMT, HNMT GAA 3432/4885MGAM 2561/4885SI 1937/4885
US-11780836-B2 Process of preparing a PD-1/PD-L1 inhibitor PDCD1, CD274, PDCD1LG2 GAA 1241/4885MGAM 2111/4885SI 1310/4885
US-20240376106-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR PDCD1, CD274, PDCD1LG2 GAA 1241/4885MGAM 2111/4885SI 1310/4885
US-20220144830-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR PDCD1, CD274, PDCD1LG2 GAA 1241/4885MGAM 2111/4885SI 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.